Full Coverage

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

                   
yahoo.com
May 21, 2008
        
Story Timeline:  197 days

Wednesday May 21, 9:00 am ET - Innovative pipeline products highlight Watson's commitment to urology - The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of... [read full story]                    

Add Comment
Latest article on this story:

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

 drugs.com May 22, 2008
First article on this story:

Watson: Positive Phase 3 data for silodosin and oxybutynin chloride topical gel

 finanznachrichten.de May 21, 2008
Selected publications with coverage of this story:
redorbit.com medicalnewstoday.com yahoo.com drugs.com finanznachrichten.de
RELATED
Found 4 documents:
                   

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

drugs.com
May 22, 2008
        

- Innovative pipeline products highlight Watson's commitment to urology - ORLANDO, Fla., May 21, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented...

Watson Reports Positive Phase III Data for Prostate and Bladder Drugs

redorbit.com
May 22, 2008
        

Watson Pharmaceuticals has announced positive data from clinical studies on two Phase III products - silodosin, an investigational treatment for benign prostatic hyperplasia and oxybutynin chloride topical gel, an investigational product for overactive bladder.

                   

Watson Announces Positive Data For Its New Investigational Products For Benign Prostatic...

medicalnewstoday.com
May 22, 2008
        

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstract (Steady-State Pharmacokinetics of an Investigational...

Watson: Positive Phase 3 data for silodosin and oxybutynin chloride topical gel

finanznachrichten.de
May 21, 2008
        

NEW YORK (Thomson Financial) - Watson Pharmaceuticals Inc. Wednesday said it received positive results from Phase 3 trials for investigational enlarged prostate treatment silodosin and investigational overactive bladder product oxybutynin chloride topical gel. The silodosin safety trial showed...